^{Defeating the world’s deadliest infectious diseases}

We are entering Phase 1a clinical development with our first-in-class and best-in-class synthetic glycoconjugate vaccines targeting highly conserved elements across pathogens, including malaria, tuberculosis and invasive fungal infections, to deliver unprecedented protection with scalable, cost-efficient production and a target product profile aligned with global rollout.